Overview Dividends

(OLMA) Olema Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68062P1066

Palazestrant, OP-3136, KAT6 Inhibitor, Oncology

Biotechnology
Market Cap in USD: 2,200m

IPO / Inception: 2020-11-19
Return 12m vs S&P 500: 286%

EPS (Earnings per Share)

EPS CAGR: 3.79%
EPS Trend: 55.2%

Last SUE: -0.08
Qual. Beats: 0

Revenue

Rev. CAGR: 0.00%
Rev. Trend: 9.1%

Last SUE: 0.00
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	88.1%
Value at Risk 5%th	128%
Relative Tail Risk	-11.93%

Reward TTM
Sharpe Ratio	1.38
Alpha	298.37
CAGR/Max DD	1.40

Character TTM
Hurst Exponent	0.708
Beta	0.271
Beta Downside	0.056

Drawdowns 3y
Max DD	82.15%
Mean DD	34.40%
Median DD	30.72%

Description: OLMA Olema Pharmaceuticals October 27, 2025

Olema Pharmaceuticals (NASDAQ: OLMA) is a clinical-stage biotech that concentrates on novel therapies for women’s cancers, principally estrogen-receptor-positive (ER+) breast cancer. Its flagship asset, palazestrant, is a dual-action estrogen receptor antagonist and selective degrader currently being evaluated in a pivotal Phase 3 trial (OPERA-01) as monotherapy for second- or third-line metastatic ER+/HER2- disease.

The company’s pipeline extends palazestrant into combination regimens with CDK4/6 inhibitors (palbociclib, ribociclib), the PI3Kα inhibitor alpelisib, and the mTOR inhibitor everolimus in early-stage Phase 1/2 studies, aiming to overcome resistance mechanisms. Olema is also advancing OP-3136, an oral KAT6 inhibitor, which entered Phase 1 trials for ER+/HER2- metastatic breast cancer and other solid tumors.

As of the latest 10-Q, Olema reported a cash runway of roughly $120 million, sufficient to fund its current trial portfolio through mid-2026, and a market-cap near $250 million-reflecting a price-to-cash-burn multiple of about 2×, modest by biotech standards. The ER-degrader space is heating up, with FDA approvals of competitors such as elacestrant highlighting both market opportunity (global ER+ breast cancer therapeutics market projected to exceed $15 billion by 2028) and pricing pressure. For a deeper quantitative view of OLMA’s risk-adjusted upside, you may find the ValueRay platform’s analyst notes worth reviewing.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-150.0m TTM) > 0 and > 6% of Revenue (6% = 21.8k TTM)

FCFTA -0.38 (>2.0%) and ΔFCFTA 3.80pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 80.4k% (prev 9941 %; Δ 70.5kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.38 (>3.0%) and CFO -134.7m > Net Income -150.0m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 8.03 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (85.7m) change vs 12m ago 49.72% (target <= -2.0% for YES)

Gross Margin 14.84% (prev 80.63%; Δ -65.79pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 0.12% (prev 0.82%; Δ -0.69pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -13.75 (EBITDA TTM -161.3m / Interest Expense TTM -11.8m) >= 6 (WARN >= 3)

Altman Z'' -16.25

(A) 0.83 = (Total Current Assets 334.3m - Total Current Liabilities 41.7m) / Total Assets 352.5m

(B) -1.56 = Retained Earnings (Balance) -551.5m / Total Assets 352.5m

warn (B) unusual magnitude: -1.56 — check mapping/units

(D) -12.25 = Book Value of Equity -551.0m / Total Liabilities 45.0m

Total Rating: -16.25 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 34.83

1. Piotroski 0.0pt

2. FCF Yield -7.18%

3. FCF Margin data missing

4. Debt/Equity 0.01

5. Debt/Ebitda 0.19

6. ROIC - WACC (= -51.63)%

7. RoE -41.51%

8. Rev. Trend 9.12%

9. EPS Trend 55.18%

What is the price of OLMA shares?

As of December 30, 2025, the stock is trading at USD 25.64 with a total of 1,095,623 shares traded.
Over the past week, the price has changed by -9.01%, over one month by -8.26%, over three months by +168.76% and over the past year by +357.04%.

Is OLMA a buy, sell or hold?

Olema Pharmaceuticals has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy OLMA.

Strong Buy: 5
Buy: 3
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the OLMA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	46	79.4%
Analysts Target Price	46	79.4%
ValueRay Target Price	28.9	12.6%

OLMA Fundamental Data Overview December 27, 2025

Market Cap USD = 2.20b (2.20b USD * 1.0 USD.USD)
P/B = 7.156
Beta = 1.882
Revenue TTM = 364.0k USD
EBIT TTM = -161.7m USD
EBITDA TTM = -161.3m USD
Long Term Debt = 3.00m USD (from longTermDebt, last quarter)
Short Term Debt = 1.17m USD (from shortTermDebt, last quarter)
Debt = 4.48m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -30.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.88b USD (2.20b + Debt 4.48m - CCE 329.0m)
Interest Coverage Ratio = -13.75 (Ebit TTM -161.7m / Interest Expense TTM -11.8m)
FCF Yield = -7.18% (FCF TTM -134.7m / Enterprise Value 1.88b)
FCF Margin = -37.0k% (FCF TTM -134.7m / Revenue TTM 364.0k)
Net Margin = -41.2k% (Net Income TTM -150.0m / Revenue TTM 364.0k)
Gross Margin = 14.84% ((Revenue TTM 364.0k - Cost of Revenue TTM 310.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 5.32 (Enterprise Value 1.88b / Total Assets 352.5m)
Interest Expense / Debt = 29.39% (Interest Expense 1.32m / Debt 4.48m)
Taxrate = 0.00% (-1.0 / -129.5m)
NOPAT = -161.7m (EBIT -161.7m * (1 - 0.00%)) [loss with tax shield]
Current Ratio = 8.03 (Total Current Assets 334.3m / Total Current Liabilities 41.7m)
Debt / Equity = 0.01 (Debt 4.48m / totalStockholderEquity, last quarter 307.5m)
Debt / EBITDA = 0.19 (negative EBITDA) (Net Debt -30.8m / EBITDA -161.3m)
Debt / FCF = 0.23 (negative FCF - burning cash) (Net Debt -30.8m / FCF TTM -134.7m)
Total Stockholder Equity = 361.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.55% (Net Income -150.0m / Total Assets 352.5m)
RoE = -41.51% (Net Income TTM -150.0m / Total Stockholder Equity 361.3m)
RoCE = -44.39% (EBIT -161.7m / Capital Employed (Equity 361.3m + L.T.Debt 3.00m))
RoIC = -44.58% (negative operating profit) (NOPAT -161.7m / Invested Capital 362.8m)
WACC = 7.06% (E(2.20b)/V(2.20b) * Re(7.01%) + D(4.48m)/V(2.20b) * Rd(29.39%) * (1-Tc(0.00)))
Discount Rate = 7.01% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 25.10%
Fair Price DCF = unknown (Cash Flow -134.7m)
EPS Correlation: 55.18 | EPS CAGR: 3.79% | SUE: -0.08 | # QB: 0
Revenue Correlation: 9.12 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.54 | Chg30d=+0.013 | Revisions Net=+2 | Analysts=4
EPS next Year (2026-12-31): EPS=-2.33 | Chg30d=-0.053 | Revisions Net=-1 | Growth EPS=-20.7% | Growth Revenue=+0.0%

Additional Sources for OLMA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle